The ability of hydroxysafflor yellow a to attenuate lipopolysaccharide- induced pulmonary inflammatory injury in mice

Phytotherapy Research

Volumn 24, Issue 12, 2010, Pages 1788-1795

  Sun, Chun Yan ^a   Pei, Chong Qiang ^a   Zang, Bao Xia ^a   Wang, Lin ^a   Jin, Ming ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

hydroxysafflor yellow A; lipopolysaccharide; pulmonary inflammatory injury

Indexed keywords

BICARBONATE; HYDROXYSAFFLOR YELLOW A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOPEROXIDASE; SAFFLOWER EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD PH; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG EDEMA; LUNG FLUID; MALE; MOUSE; NONHUMAN; OXYGEN SATURATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAFFLOWER; WESTERN BLOTTING;

ACUTE LUNG INJURY; ANIMALS; BLOOD GAS ANALYSIS; CHALCONE; CYTOKINES; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEROXIDASE; QUINONES; TRANSCRIPTION FACTOR RELA;

ANIMALIA; CARTHAMUS TINCTORIUS; MUS;

EID: 78649670589     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3166     Document Type: Article

References (25)

1. Abraham E., 2003. Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis 187: S362-S369.
2. Arcaroli J, Yum HK, Kupfner J, Park JS, Yang KY, Abraham E., 2001. Role of p38 MAP kinase in the development of acute lung injury. Clin Immunol 101: 211-219.
3. Bhatia M, Moochhala S., 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 202: 145-156.
4. Blackwell TS, Christman JW., 1997. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 17: 3-9.
5. Bosma K, Fanelli V, Ranieri VM., 2005. Acute respiratory distress syndrome: update on the latest developments in basic and clinical research. Curr Opin Anaesthesiol 18: 137-145.
6. Calfee CS, Matthay MA., 2007. Nonventilatory treatments for acute lung injury and ARDS. Chest 131: 913-920.
7. Chen TT, Du YJ, Liu XL, Zhu HB., 2008. Inhibitory action of hydroxysafflor yellow A on inflammatory signal transduction pathway related factors in rats with cerebral cortex ischemia. Yao Xue Xue Bao 43: 570-575.
8. Fan J, Ye RD, Malik AB., 2001. Transcriptional mechanisms of acute lung injury. Am J Physiol Lung Cell Mol Physiol 281: 1037-1050.
9. Garrean S, Gao XP, Brovkovych V, et al,. 2006. Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J Immunol 177: 4853-4860.
10. Giebelen IA, van Westerloo DJ, Larosa GJ, de Vos AF, Van der Poll T., 2007. Local stimulation of alpha7 cholinergic receptors inhibits LPS-induced TNF-alpha release in the mouse lung. Shock 28: 700-703.
11. Godowski PJ., 2005. A smooth operator for LPS responses. Nat Immunol 6: 544-546.
12. Haddad EB, Birrell M, McCluskie K, et al,. 2001. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol 132: 1715-1724.
13. He HY, Wang C, Pang BS., 2008. Effects of activated protein C on coagulation and fibrinolysis in rabbits with endotoxin induced acute lung injury. Chin Med J 121: 2561-2565.
14. Hudson LD, Milberg JA, Anardi D, Maunder RJ., 1995. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 151: 293-301.
15. Jin M, Wu W, Li JR., 2004. Study on anticoagulant effect of HSYA. Zhong Cao Yao 35: 665-666.
16. Koroush K, Jean-Pierre G, Chen MH, Chen DF, Zhang DX., 2002. Characterization of a murine model of endotoxin-induced acute lung injury. Shock 17: 300-303.
17. Minamino T, Komuro I., 2006. Regeneration of the endothelium as a novel therapeutic strategy for acute lung injury. J Clin Invest 116: 2316-2319.
18. Nick JA, Young SK, Brown KK, et al,. 2000. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol 164: 2151-2159.
19. Schnyder-Candrian S, Quesniaux VF, Di Padova F, et al,. 2005. Dual effects of p38 MAPK on TNF-dependent bronchoconstriction and TNF-independent neutrophil recruitment in lipopolysaccharide-induced acute respiratory distress syndrome. J Immunol 175: 262-269.
20. Wang T, Fu F, Han B, Zhang L., 2006. Mechanism of Hydroxysafflor yellow A on protecting ischemic myocardium. J Mol Cell Cardiol 40: 957.
21. Ware LB, Fang X, Matthay MA., 2003. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 285: L514-L521.
22. Ware LB, Matthay MA., 2000. The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349.
23. Ye SY, Gao WY., 2008. Hydroxysafflor yellow A protects neuron against hypoxia injury and suppresses inflammatory responses following focal ischemia reperfusion in rats. Arch Pharm Res 31: 1010-1015.
24. Zang BX, Jin M, Li JR., 2007. Study on anti-oxidative effect of HSYA. Zhong Cao Yao 38: 741-743.
25. Zang BX, Jin M, Li JR., 2008. Large scale preparation of pure Hydroxysafflor Yellow A by macroporous resin-gel column chromatography. J Cardiovasc Pulm Dis 27: 363-365.